Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 11/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718857 | 0.83 | RIPK1 (0.45) | KCNK3RIPK1CNR2CNR1 | |
| SCHEMBL182444 | 0.79 | BRD4 (0.42) | KCNK3 | |
| SCHEMBL13889288 | 0.78 | USP30 (0.48) | HTR4RIPK1CNR2CNR1KMT2A | |
| SCHEMBL182170 | 0.77 | BRD4 (0.41) | KCNK3 | |
| SCHEMBL13871533 | 0.76 | CNR2 (0.55) | CNR2CNR1 | |
| SCHEMBL14003157 | 0.76 | CNR2 (0.47) | CNR2CNR1KMT2A | |
| SCHEMBL2712623 | 0.75 | CYP3A4 (0.46) | KMT2A | |
| SCHEMBL2717254 | 0.74 | CNR2 (0.65) | RIPK1CNR2CNR1KMT2A | |
| SCHEMBL13871536 | 0.74 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL5811700 | 0.71 | CNR2 (0.61) | RIPK1CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735286-B1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-04 | — | — | EP | disclosed |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | LAGU BHARAT | 2009-04-16 | — | — | US | disclosed |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | LAGU BHARAT | 2009-04-16 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | CNR2, CNR1, GPR18 | HTR4 54/4885KCNK3 987/4885RIPK1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.